• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions

    Reed-Lane

    Baxter BioPharma Solutions

    test company saurabh
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Adare Pharma Solutions

    Almac Group

    Baxter BioPharma Solutions

    test company saurabh
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Unfolding Pharma Product Mix

    Should you be diversifying your product portfolio to include production of small molecules and biologics?

    The Unfolding Pharma Product Mix
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Mogene
    • Regis Custom Pharma
    Ben Locwin, Contributing Writer04.05.19
    If you’ve ever been to business school, or taken an operations management course at any point, there is always a section on Product Mix. It typically goes something like this:

    CP Furniture (CEO Tim Wright) makes swanky conference event furniture. The production process for each is similar in that both require a certain number of labor hours in the carpentry department, and a certain number of labor hours in the painting department. Each table takes 4 hours of carpentry work and 2 hours of painting work. Each chair requires 3 hours in carpentry time and 1 hour in painting. During the current production period, 240 hours of carpentry time and 100 hours of painting time are available. The marketing personnel are confident that they can sell all the tables that are made. However, due to an existing inventory of chairs, they want to make no more than 60 new chairs. Each table sold results in a profit contribution of $7, and each chair sold yields a profit contribution of $5. What’s the optimum mix of chairs and tables to maximize worker efficiency, utility, and net profits?

    Then the students typically turn to linear programming or something like Excel’s (semi-flawed) Solver algorithm to work through a very controlled calculation. These calculations don’t take into account the potential for stock-outs of materials at the suppliers, worker strikes, changes in customer preferences for chairs vs. tables, et cetera. So in a very real sense, our next generation of business minds are being lulled into thinking that a simple Solver output is all that’s needed in the real world. This is simply not true.

    Small Molecules vs. Biologics
    A small molecule is typically defined as a drug product that is of 900 Daltons in size or smaller. They generally exert their effects amidst biochemical reactions within the body. In pharmacology, small molecule as a term is usually reserved for specific molecular cases that bind to certain macromolecules to act as ‘effectors.’ In our industry, we use it a bit more loosely, but the general principles remain. With a size under 900 Daltons (< ~1 nanometer), small molecules can diffuse relatively easily across cell membranes and be transcellularly transported across intestinal epithelial cells quickly. When small molecules under ~500 Daltons are used, lower rates of clinical attrition tend to follow, which has become a consideration of note for many years (cf. Lipinski’s Rule of Five).

    A biologic tends to be large and complex. They are generally made in genetically engineered cells that impose their own variation—such as with post-translation modifications—on the outcomes of the drug manufacturing processes. The FDA suggests that “Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources—human, animal, or microorganism—and may be produced by biotechnology methods and other cutting-edge technologies.”1 Biologics can interact with challenging biochemical targets in vivo, which have thus far eluded small molecule drugs. The best examples of this are protein-protein interactions which are characterized by large, and sometimes, flat surfaces with few electrically-charged pockets.

    Manufacturing of biologicals tends to be much more challenging—complexity, time, potential for difficult-to-predict failure—than for traditional small molecule drugs. Even minor or seemingly-insignificant changes in manufacturing process can cause dramatic changes in efficacy or immunogenicity (see Table 1: Characteristics of small molecule drugs compared to biologics2).


     


    Because of the differences of these two entities, manufacturers are always faced with the real-world version of the fake-world business class challenge posed above: Should you add biologics into your product mix? If you only make biologics, should you also have a portfolio that includes small molecules? What ratio is the ‘right’ ratio for these two forms of therapy to maximize your facility’s up-time and profitability? All good questions. Here are some answers:

    When in doubt, diversify
    This is a typically-recited statement among financial investors, because to a large degree, spreading out your risk into a variety of potential funds tends to lead to more stable and predictable profitability as time goes on. In this way, diversification can contribute to stability by averaging the components of noise from a variety of different assets. The same could be true, though not necessarily so, in diversifying your product portfolio, up to and including combining production of small molecules and biologics.

    Cost to the consumer matters. A lot.

    Just because there’s a breakthrough drug doesn’t mean that people will buy it. Or that insurers will pay for it. The issue here is fundamentally market penetration. You can’t get a return on investment for a complex manufacturing process if you overprice the drug. You can readily find a variety of cost models for small molecules vs. biologics, but a relatively accurate one puts the cost of an averaged, daily small molecule treatment at ~$1/day. Whereas biologics can easily be $22/day or greater.3

    Research conducted by Evaluate Pharma several years ago positioned biologics as a growing trend, where biologic products accounted for 17% of sales of the top 100 pharma products in 2004; 34% in 2011 and were forecasted to represent 50% in 2016. We now know the composition of the current Top 10 pharma products and the domination in large part thereof from biologics. So there is real demand and dollars there. But small molecules are assuredly still very effective ligands, can be quicker to development, and had also been approved by FDA at a rate of 2:1 over biologics. Although, that’s also subject to a considerable amount of year-to-year fluctuation, averaged industry pipelines being what they are. Also, don’t forget that having the option now of combining biologics with more well-defined chemical entities in the form of antibody-drug conjugates (immunoconjugates) represents yet another way to diversify product mix. 

    Optimizing product mix
    Understand that a product mix in this context has two fundamental components: Product mix width and consistency.* Product mix ‘width’ refers to the number of product lines ‘wide’ within a facility. This is diversification of the portfolio. Product mix ‘consistency’ refers to how closely related the product lines are in terms of end use, production requirements, distribution channels or any other business concern. 

    In order to properly appraise the optimal product mix for your facility, run length, batch sizes, distribution, costing analysis (per batch), error (defect, failure) rates, total uptime/downtime, and capital intensity must be used to solve this. It becomes a bit more complicated than the table and chairs example, but the overall principle is the same and becomes a formulation of linear optimization. Some of this shares a pedigree with John von Neumann’s conjecture on the theory of duality from game theory.

    Additionally, my Author’s Pro tip: Approaching your product mix calculations properly matters. A lot. Dantzig’s original example for linear programming was to optimally assign 70 people to 70 different roles (jobs). The number of configurations for this exceeds the number of particles in the known universe. For a reasonable supply chain complexity that could exceed this, you may not get an answer for a long, long time. Try a linear optimization method using your calculated inputs and save yourself from an incorrect answer, as well as perhaps 110,000 years of computation time. 

    *There’re really 4 components, but the additional two are the product mix ‘length’ and one is product mix ‘depth.’ The product mix ‘length’ is how many different sellable items there are within a product line. This is generally one in pharma. The product mix ‘depth’ is one that we can virtually disregard in the pharmaceutical industry, because it refers to the number of different variations within a vertical of the product mix. One setup (train) of a small molecule or biologic produces a (hopefully QbD) output. There aren’t different flavors.

    References
    1. United States Food and Drug Administration. (2019). What are “biologics” questions and answers. https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm
    2. Declerck PJ. Biologicals and biosimilars: a review of the science and its implications. Generics and Biosimilars Initiative Journal (GaBI J). 2012;1(1):13-6.
    3. GaBI Online - Generics and Biosimilars Initiative. Opportunities for biosimilar development. Mol, Belgium: Pro Pharma Communications International; [cited 2012 Jun 29]. Author’s note: remember that prices are continuously in flux, and so even more recent calculations on this aren’t necessarily more accurate.



    Ben Locwin

    Ben Locwin, PhD, MBA, MS, MBB began his foray into healthcare decades ago after he started out as an astrophysicist. He is a popularizer and communicator of science, and has worked in a variety of pharmaceutical organizations (small molecule and biologics), medical device organizations, and within hospitals, clinics, and emergent care centers bringing better healthcare to the end user (i.e., the patients!).
    Related Searches
    • biosimilars
    • facility
    • production
    • supply chain
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Mogene Mogene
    Regis Custom Pharma Regis Custom Pharma
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    Clinical Trial Supply & Logistics Clinical Trial Supply & Logistics
    Synthetic Control Arms Synthetic Control Arms
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?
    Drugs as...Fashion? Drugs as...Fashion?
    A Government-run Drug Manufacturer? A Government-run Drug Manufacturer?
    Aphena Ready for Opioid Crisis Response Act Aphena Ready for Opioid Crisis Response Act

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20


    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20


    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20

    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20


    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20


    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20

    • Vision: 2020

      Vision: 2020

      You have exactly 366 days in 2020 to bring your clarity of vision to reality.
      Ben Locwin 01.28.20

    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    Trending
    • Century Therapeutics Significantly Expands Capabilities
    • Catalent Acquires Delphi Genetics
    • Sanofi And Translate Bio Expand Vaccine Collaboration
    • RotaChrom Technologies Partners With Cyclolab
    • Inside A Vaccine Trial
    Breaking News
    • Altasciences Contributes to Vibegron Approval
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Terumo to Purchase Predictive Analytics Firm Health Outcomes Sciences
    Abiomed Leader Michael Minogue Named AdvaMed Board Chairman
    TransEnterix Changes Name to Asensus Surgical
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Altasciences Contributes to Vibegron Approval
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Afro Sheen Launches New Brand Initiatives
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Implants for Use in Spinal Surgeries Become Available
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login